UK pharmaceutical conglomerate AstraZeneca secured a landmark ruling last Friday when a jury in federal court found the firm did not harm competition through a pay-for-delay scheme with India-based generics firm Ranbaxy.
According to reports, while the jury found that AstraZeneca had made unjustified payments to Ranbaxy to delay the release of a generic form of a competitive drug, the jury said those payments were not unreasonably anticompetitive because no competing company had the regulatory clearance to sell that generic drug.
The case was the first pay-for-delay suit since the US Supreme Court sided with the Federal Trade Commission in ruling that such agreements could be deemed anticompetitive.
Dozens of drugstore chains, wholesalers and potentially hundreds of thousands of class members had sued AstraZeneca for violating antitrust law when it paid Ranbaxy to delay the release of the generic, cheaper form of Nexium. AstraZeneca reportedly faced up to $10 billion in fines.
Full content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
ConocoPhillips Acquires Marathon Oil for $22.5 Billion in Major Energy Sector Consolidation
May 29, 2024 by
CPI
Judge Denies Amazon’s Bid to Dismiss FTC Lawsuit Over Prime Membership Practices
May 29, 2024 by
CPI
Germany and France Advocate for Major EU Competition Reform
May 29, 2024 by
CPI
Equifax Accused of Monopolizing Employment Verification Market in New Suit
May 29, 2024 by
CPI
Car Battery Makers to Challenge EU Cartel Charges in Brussels
May 29, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Merger Guidelines Retrospective
May 21, 2024 by
CPI
Mergers of Complements
May 21, 2024 by
CPI
Personality Traits, Private Equity, and Merger Analysis
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Lessons in the Importance of Incipiency, Modern Economics, and Monopsony
May 21, 2024 by
CPI
The 2023 Merger Guidelines: Sharpening Merger Analysis
May 21, 2024 by
CPI